Premium
Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies
Author(s) -
Jeha Sima,
Crews Kristine R.,
Pei Deqing,
Peyton Melissa,
Panetta John C.,
Ribeiro Raul C.,
Zhao Xujie,
Campbell Patrick,
Metzger Monika L.,
Yang Jun J.,
Cheng Cheng,
Pui ChingHon,
Bhojwani Deepa
Publication year - 2021
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33465
Subject(s) - medicine , bendamustine , clofarabine , etoposide , refractory (planetary science) , gastroenterology , salvage therapy , dexamethasone , surgery , leukemia , cytarabine , chemotherapy , lymphoma , rituximab , physics , astrobiology
Background A phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies. Methods Patients younger than 22 years with second or greater relapsed or refractory acute leukemia or lymphoma after 2 or more prior regimens were eligible. With the rolling 6 design, participants received escalating doses of bendamustine (30, 40, or 60 mg/m 2 /d) in combination with clofarabine (40 mg/m 2 ), etoposide (100 mg/m 2 ), and dexamethasone (8 mg/m 2 ) daily for 5 days. Optional pharmacokinetic studies were performed in cycle 1 on day 1 and day 5. Results Sixteen patients were enrolled. Six patients were treated at the dose level of 30 mg/m 2 /d, 6 were treated at the dose level of 40 mg/m 2 /d, and 4 were treated at the dose level of 60 mg/m 2 /d. The dose‐limiting toxicity was prolonged myelosuppression. The combination was otherwise well tolerated. The recommended dose of bendamustine in this combination was 30 mg/m 2 /d for 5 days. Ten responses were observed after 1 cycle: 6 complete remissions, 1 durable minimal residual disease–negative complete remission without platelet recovery in a patient with early T‐cell precursor leukemia, and 3 partial remissions. Six patients proceeded to transplantation. The event‐free survival rate was 40.6% (95% confidence interval [CI], 17.5%‐63.7%) at 1 year and 33.9% (95% CI, 11.9%‐55.9%) at 3 years. Conclusions Bendamustine is well tolerated in combination with clofarabine, etoposide, and dexamethasone. The combination administered over 5 days is effective for multiple relapsed and refractory hematologic malignancies. This trial is registered with ClinicalTrials.gov (NCT01900509). Lay Summary Improvements to the existing chemotherapy regimen are still needed for patients who relapse after targeted therapies and immunotherapies and for those who are not eligible for or have no access to such therapies. A regimen combining cyclophosphamide, clofarabine, and etoposide has been used in relapsed and refractory pediatric patients with hematologic malignancies. This study shows that substituting bendamustine for cyclophosphamide in combination with clofarabine and etoposide is safe and effective.